Therapeutic drug monitoring (TDM) of antiretroviral drugs is performed in selected HIV-positive patients. The aim of this study was to estimate the prevalence of undetectable plasma concentrations of ritonavir and boosted PIs and to evaluate the association between those and the 48 week risk of virological failure.
Therapeutic drug monitoring of boosted PIs in HIV-positive patients: undetectable plasma concentrations and risk of virological failure
CALCAGNO, Andrea
First
;PAGANI, NICOLE;ARIAUDO, ALESSANDRA;CARCIERI, CHIARA;D'AVOLIO, ANTONIO;MARINARO, Letizia;TRENTINI, Laura;DI PERRI, Giovanni;BONORA, Stefano
Last
2017-01-01
Abstract
Therapeutic drug monitoring (TDM) of antiretroviral drugs is performed in selected HIV-positive patients. The aim of this study was to estimate the prevalence of undetectable plasma concentrations of ritonavir and boosted PIs and to evaluate the association between those and the 48 week risk of virological failure.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
dkx052.pdf
Accesso riservato
Tipo di file:
PDF EDITORIALE
Dimensione
118.1 kB
Formato
Adobe PDF
|
118.1 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
